Indication
In combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC) at high risk of recurrence.

Medicine details

Medicine name:
pertuzumab (Perjeta)
SMC ID:
SMC2197
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Publication due date:
07 October 2019
SMC meeting date:
03 September 2019
Patient group submission deadline:
01 July 2019